PortalPublikationenShort-term versus long-term antiarrhythmic drug treatment af...

Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial.

Standard

Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. / Kirchhof, Paulus; Andresen, Dietrich; Bosch, Ralph; Borggrefe, Martin; Meinertz, Thomas; Parade, Ulli; Ravens, Ursula; Samol, Alexander; Steinbeck, Gerhard; Treszl, András; Wegscheider, Karl; Breithardt, Günter.

in: LANCET, Jahrgang 380, Nr. 9838, 9838, 2012, S. 238-246.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kirchhof, P, Andresen, D, Bosch, R, Borggrefe, M, Meinertz, T, Parade, U, Ravens, U, Samol, A, Steinbeck, G, Treszl, A, Wegscheider, K & Breithardt, G 2012, 'Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial.', LANCET, Jg. 380, Nr. 9838, 9838, S. 238-246. <http://www.ncbi.nlm.nih.gov/pubmed/22713626?dopt=Citation>

APA

Kirchhof, P., Andresen, D., Bosch, R., Borggrefe, M., Meinertz, T., Parade, U., Ravens, U., Samol, A., Steinbeck, G., Treszl, A., Wegscheider, K., & Breithardt, G. (2012). Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. LANCET, 380(9838), 238-246. [9838]. http://www.ncbi.nlm.nih.gov/pubmed/22713626?dopt=Citation

Vancouver

Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. LANCET. 2012;380(9838):238-246. 9838.

Bibtex

@article{a7135ae737894eeebd1dd47085c2ddc4,
title = "Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial.",
abstract = "Antiarrhythmic drugs prolong the atrial action potential and refractory period, and thereby prevent recurrent atrial fibrillation after cardioversion. The atrial action potential normalises after 2-4 weeks of sinus rhythm, suggesting that antiarrhythmic drugs might not be needed beyond that period. Therefore, we investigated whether short-term antiarrhythmic drug treatment after cardioversion is non-inferior to long-term treatment.",
author = "Paulus Kirchhof and Dietrich Andresen and Ralph Bosch and Martin Borggrefe and Thomas Meinertz and Ulli Parade and Ursula Ravens and Alexander Samol and Gerhard Steinbeck and Andr{\'a}s Treszl and Karl Wegscheider and G{\"u}nter Breithardt",
year = "2012",
language = "English",
volume = "380",
pages = "238--246",
journal = "LANCET",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9838",

}

RIS

TY - JOUR

T1 - Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial.

AU - Kirchhof, Paulus

AU - Andresen, Dietrich

AU - Bosch, Ralph

AU - Borggrefe, Martin

AU - Meinertz, Thomas

AU - Parade, Ulli

AU - Ravens, Ursula

AU - Samol, Alexander

AU - Steinbeck, Gerhard

AU - Treszl, András

AU - Wegscheider, Karl

AU - Breithardt, Günter

PY - 2012

Y1 - 2012

N2 - Antiarrhythmic drugs prolong the atrial action potential and refractory period, and thereby prevent recurrent atrial fibrillation after cardioversion. The atrial action potential normalises after 2-4 weeks of sinus rhythm, suggesting that antiarrhythmic drugs might not be needed beyond that period. Therefore, we investigated whether short-term antiarrhythmic drug treatment after cardioversion is non-inferior to long-term treatment.

AB - Antiarrhythmic drugs prolong the atrial action potential and refractory period, and thereby prevent recurrent atrial fibrillation after cardioversion. The atrial action potential normalises after 2-4 weeks of sinus rhythm, suggesting that antiarrhythmic drugs might not be needed beyond that period. Therefore, we investigated whether short-term antiarrhythmic drug treatment after cardioversion is non-inferior to long-term treatment.

M3 - SCORING: Journal article

VL - 380

SP - 238

EP - 246

JO - LANCET

JF - LANCET

SN - 0140-6736

IS - 9838

M1 - 9838

ER -